Literature DB >> 7651619

Three immediate early gene response elements in the proximal preprotachykinin-A promoter in two functionally distinct domains.

J M Paterson1, S C Mendelson, J McAllister, C F Morrison, S Dobson, C Grace, J P Quinn.   

Abstract

The preprotachykinin-A promoter contains two blocks of DNA sequence, with a high degree of homology to one another, both containing activator protein 1/cAMP response element-like elements which constitute cis-acting regulatory domains. These two domains are differentially regulated in HeLa cells and primary cultures of dorsal root ganglion neurons when they are placed in the context of a reporter gene driven by the c-fos minimum promoter. One of the domains, corresponding to a region of the preprotachykinin promoter spanning nucleotides -345 to -308, contains two activator protein 1 elements adjacent to an E-box binding protein consensus sequence. Both of the activator protein 1 elements can bind a complex containing c-fos/c-fos related antigen proteins and the adjacent E-box element is specifically recognized by proteins present in HeLa nuclear extract. This domain requires the synergistic action of both activator protein 1 elements to drive expression of the reporter gene in both HeLa and dorsal root ganglion cells. The second or proximal domain spans nucleotides -198 to -155 and contains a previously characterized activator protein 1/cAMP response element/ATF enhancer element which, in contrast to the activator protein 1 elements in the distal domain, functions in both HeLa and dorsal root ganglion cells as one copy. This domain is differentially regulated in HeLa and dorsal root ganglia. The previously characterized enhancer activity is repressed in the context of the extended cis-acting domain in HeLa cells but remains active in dorsal root ganglion, although no further enhancement of activity supported by the single enhancer is observed when in the context of the extended sequence. This proximal domain, in addition to binding the enhancer complex, can be bound by at least two other complexes, one of which binds to an E-box consensus sequence. As the elements corresponding to the E-box consensus in both domains cross-compete for binding of specific complex(es) it would appear that repression of the activity of the proximal domain is correlated with a specific protein complex binding adjacent to the characterized enhancer in the region spanning nucleotides -198 to -155. The preprotachykinin-A proximal promoter is therefore bound by multiple activator protein I complexes, which in the context of the cis-acting domains in which they are present can be differentially regulated. In the proximal domain their function may also be regulated in a tissue-specific manner by other proteins which bind to adjacent regulatory elements.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7651619     DOI: 10.1016/0306-4522(95)00041-g

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  4 in total

1.  Novel cell lines for the analysis of preprotachykinin A gene expression identify a repressor domain 3' of the major transcriptional start site.

Authors:  C E Fiskerstrand; P Newey; B Ebrahimi; L Gerrard; P Harrison; G P McGregor; J P Quinn
Journal:  Biochem J       Date:  1999-08-01       Impact factor: 3.857

2.  E-box motifs within the human vasopressin gene promoter contribute to a major enhancer in small-cell lung cancer.

Authors:  J M Coulson; C E Fiskerstrand; P J Woll; J P Quinn
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

3.  An upstream stimulatory factor (USF) binding motif is critical for rat preprotachykinin-A promoter activity in PC12 cells.

Authors:  J M Paterson; C F Morrison; S C Mendelson; J McAllister; J P Quinn
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

4.  Lithium chloride regulation of the substance P encoding preprotachykinin a, Tac1 gene in rat hippocampal primary cells.

Authors:  Kate Haddley; Eleanor Mary Spencer; Sylvia Argiroula Vasiliou; Mark Howard; Thimmasettappa Thippeswamy; Vivien Jill Bubb; John P Quinn
Journal:  J Mol Neurosci       Date:  2010-08-06       Impact factor: 3.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.